Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering

blonca9
May 6
1 min read

Chairman & CEO Emmanuel Savioz describes the benefits of decentralized manufacturing that is at or near the site of treatment. He highlights an armored-CAR AML program the company has with MSK in New York, and discusses Tigen's non-viral platform for NHL and multiple myeloma.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight